LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

Search

Sana Biotechnology Inc

Closed

SectorHealthcare

1.98 -1.49

Overview

Share price change

24h

Current

Min

1.95

Max

1.98

Key metrics

By Trading Economics

Income

-320K

-49M

EPS

-0.2

Employees

194

EBITDA

-1.8M

-47M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+262.5% upside

Dividends

By Dow Jones

Next Earnings

6 Aug 2025

Market Stats

By TradingEconomics

Market Cap

-47M

379M

Previous open

3.47

Previous close

1.98

News Sentiment

By Acuity

50%

50%

166 / 382 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bullish Evidence

Sana Biotechnology Inc Chart

Past performance is not a reliable indicator of future results.

Related News

23 May 2025, 20:33 UTC

Acquisitions, Mergers, Takeovers

Salesforce in Talks to Buy Informatica, Bloomberg Reports, Citing Sources

23 May 2025, 21:57 UTC

Hot Stocks

Stocks to Watch: Apple, Booz Allen, Constellation Energy, Intuit -- WSJ

23 May 2025, 21:15 UTC

Top News

Trump Threatens Fresh Tariffs on EU, iPhones and Rival Devices -- 4th Update

23 May 2025, 21:04 UTC

Acquisitions, Mergers, Takeovers

Real-Estate Broker Douglas Elliman Could See Takeover Battle After Report of Bid -- Barrons.com

23 May 2025, 20:56 UTC

Top News
Acquisitions, Mergers, Takeovers

Salesforce Back in Deal Talks With Informatica -- WSJ

23 May 2025, 20:51 UTC

Top News

Boeing in Tentative Agreement to Pay $1.1 Billion to Avoid Trial for 737 MAX Crashes -- WSJ

23 May 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

23 May 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

23 May 2025, 20:41 UTC

Top News

Stocks Fall on Tariff Broadside, After Week of Bond Market Agita -- WSJ

23 May 2025, 20:28 UTC

Top News

Trump Threatens EU With 50% Tariffs, Takes Aim at Apple; Nasdaq Drops -- WSJ

23 May 2025, 20:06 UTC

Top News

Trump Threatens Fresh Tariffs on EU, iPhones and Rival Devices -- 5th Update

23 May 2025, 20:06 UTC

Acquisitions, Mergers, Takeovers

Salesforce Stock Drops, Informatica Soars. A Deal May Be Back on the Table. -- Barrons.com

23 May 2025, 19:50 UTC

Top News

Trump's Tariffs: Where Things Stand -- 16th Update

23 May 2025, 19:28 UTC

Acquisitions, Mergers, Takeovers

Trump on Truth Social: 'Bulk of That Investment Will Occur in the Next 14 Months'

23 May 2025, 19:28 UTC

Acquisitions, Mergers, Takeovers

Trump on Truth Social: 'This Will Be a Planned Partnership Between United States Steel and Nippon Steel'

23 May 2025, 19:27 UTC

Acquisitions, Mergers, Takeovers

Trump on Truth Social: 'Proud to Announce That, After Much Consideration and Negotiation, US Steel Will REMAIN in America'

23 May 2025, 19:20 UTC

Market Talk

Crude Futures Post Modest Weekly Losses -- Market Talk

23 May 2025, 19:18 UTC

Market Talk

U.S. Natural Gas Futures End Week Unchanged -- Market Talk

23 May 2025, 18:57 UTC

Top News

Trump Threatens Fresh Tariffs on EU, iPhones and Rival Devices -- 4th Update

23 May 2025, 18:54 UTC

Top News

Trump Threatens Fresh Tariffs on EU, iPhones and Rival Devices -- Update

23 May 2025, 18:53 UTC

Top News
Acquisitions, Mergers, Takeovers

McDonald's Bids Goodbye to CosMc's, Its Space Alien-Themed Spinoff -- WSJ

23 May 2025, 18:52 UTC

Acquisitions, Mergers, Takeovers

DDC Enterprise Issues 254,333 Class A Ordinary Shrs in Exchange for 21 BTC, Valued at About $2.28M in Current Market Price

23 May 2025, 18:13 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

23 May 2025, 18:13 UTC

Market Talk

Gold Trades Higher on Reminder of Risk -- Market Talk

23 May 2025, 18:00 UTC

Top News

Apple's Stock Still Not Pricing in Trump's Demands - Heard on the Street -- WSJ

23 May 2025, 17:51 UTC

Market Talk
Earnings

Workday Sees Higher Bar for Guidance -- Market Talk

23 May 2025, 17:42 UTC

Top News

Dow Drops, Trump Threatens EU With 50% Tariffs, Takes Aim at Apple -- WSJ

23 May 2025, 17:39 UTC

Market Talk

U.S. Oil Rig Count Falls to Lowest Level Since November 2021 -- Market Talk

23 May 2025, 17:07 UTC

Top News

Trump's Tariffs: Where Things Stand -- 15th Update

23 May 2025, 17:04 UTC

Market Talk
Earnings

Workday Appears to Have Upside Potential on Conservative Outlook -- Market Talk

Peer Comparison

Price change

Sana Biotechnology Inc Forecast

Price Target

By TipRanks

262.5% upside

12 Months Forecast

Average 7.25 USD  262.5%

High 11 USD

Low 5 USD

Based on 5 Wall Street analysts offering 12 month price targets forSana Biotechnology Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

5 ratings

5

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

1.68 / 1.87Support & Resistance

Short Term

Strong Bullish Evidence

Intermediate Term

Weak Bearish Evidence

Long Term

No Evidence

Sentiment

By Acuity

166 / 382 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Sana Biotechnology Inc

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.